CLAIM CARD
Several clinically important outcomes are represented by only a single study, precluding any within-corpus replication or assessment of consistency. The safety and efficacy of exosomes for knee osteoarthritis, assessed in Bolandnazar 2024 as a randomized, triple-blind, placebo-controlled trial, showed no statistically significant difference between EV-treated and placebo groups for clinical outcomes — yet this single null finding cannot be contextualized against other human trials because no other OA-specific RCT was included. Single-trial findings, whether positive or null, carry substantial uncertainty regarding reproducibility.
Evidence grade: exploratory
Contradiction status: none
Publication: 3fa5cd13-7439-4f62-b446-2c8e84c03e7e
Provenance: Derivation Web chain
Citation Support
source_1Jafarzadeh 2025source_2Leung 2025source_3Bolandnazar 2024source_4Wu 2025source_5Kishta 2025